Intranasal nanoemulsion vaccines: An intranasal adjuvanted, recombinant influenza a/h5 vaccine candidate induces broad priming against diverse influenza a/h5n1 virus clades in a phase i. Chad costley, md/mba dr.

Prior to assuming the operational leadership of the company, he served on the. Bluewillow biologics' intranasal bird flu vaccine shows signs of broad immune response in phase i clinical trial published in nature communications new study published in nature communications. Bluewillow biologics ® is a clinical-stage biotechnology company pioneering the future of intranasal vaccines. Our best-in-class delivery platform aims to transform the prevention and treatment.